Protocol CY 4031: A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tiramsemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)
Trial ID or NCT#
NCT02496767
Status
RECRUITING
Purpose
To assess the safety, tolerability, and efficacy of the study medication, Tirasemtiv, in ALS.
Investigator(s)
Yuen So, MD, PhD
Contact us to find out if this trial is right for you.
Contact
Bona Park Purse
View on ClinicalTrials.gov